guest ::
| Home > Publications database > Pre-diagnostic Serum Glyceraldehyde-Derived Advanced Glycation End Products and Mortality Among Colorectal Cancer Patients. > print |
| Home > Publications database > Pre-diagnostic Serum Glyceraldehyde-Derived Advanced Glycation End Products and Mortality Among Colorectal Cancer Patients. > print |
| 001 | 212552 | ||
| 005 | 20240229154914.0 | ||
| 024 | 7 | _ | |a 10.1002/ijc.34449 |2 doi |
| 024 | 7 | _ | |a pmid:36715363 |2 pmid |
| 024 | 7 | _ | |a 0020-7136 |2 ISSN |
| 024 | 7 | _ | |a 1097-0215 |2 ISSN |
| 024 | 7 | _ | |a altmetric:141974028 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-00237 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Mao, Ziling |b 0 |
| 245 | _ | _ | |a Pre-diagnostic Serum Glyceraldehyde-Derived Advanced Glycation End Products and Mortality Among Colorectal Cancer Patients. |
| 260 | _ | _ | |a Bognor Regis |c 2023 |b Wiley-Liss |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1681198925_5541 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2023 Jun 1;152(11):2257-2268 |
| 520 | _ | _ | |a Glyceraldehyde-derived advanced glycation end products (glycer-AGEs) could contribute to colorectal cancer development and progression due to their pro-oxidative and pro-inflammatory properties. However, the association of glycer-AGEs with mortality after colorectal cancer diagnosis has not been previously investigated. Circulating glycer-AGEs were measured by competitive ELISA. Multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for associations of circulating glycer-AGEs concentrations with CRC-specific and all-cause mortality among 1,034 colorectal cancer (CRC) cases identified within the European Prospective Investigation into Cancer and Nutrition (EPIC) study between 1993 and 2013. During a mean of 48 months of follow-up, 529 participants died (409 from CRC). Glycer-AGEs were statistically significantly positively associated with CRC-specific (HRQ5 vs Q1 =1.53, 95%CI: 1.04-2.25, Ptrend =0.002) and all-cause (HRQ5 vs Q1 =1.62, 95%CI: 1.16-2.26, Ptrend <0.001) mortality among individuals with CRC. There was suggestion of a stronger association between glycer-AGEs and CRC-specific mortality among patients with distal colon cancer (per SD increment: HRproximal colon =1.02, 95%CI: 0.74-1.42; HRdistal colon =1.51, 95%CI: 1.20-1.91; Peffect modification =0.02). The highest HR was observed among CRC cases in the highest body mass index (BMI) and glycer-AGEs category relative to lowest BMI and glycer-AGEs category for both CRC-specific (HR=1.78, 95%CI: 1.02-3.01) and all-cause mortality (HR=2.15, 95%CI: 1.33-3.47), although no statistically significant effect modification was observed. Our study found that pre-diagnostic circulating glycer-AGEs are positively associated with CRC-specific and all-cause mortality among individuals with CRC. Further investigations in other populations and stratifying by tumor location and BMI are warranted. This article is protected by copyright. All rights reserved. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Glyceraldehyde-derived advanced glycation end products |2 Other |
| 650 | _ | 7 | |a advanced glycation end products |2 Other |
| 650 | _ | 7 | |a colorectal cancer |2 Other |
| 650 | _ | 7 | |a mortality |2 Other |
| 650 | _ | 7 | |a prospective study |2 Other |
| 700 | 1 | _ | |a Baker, Jacqueline Roshelli |b 1 |
| 700 | 1 | _ | |a Takeuchi, Masayoshi |b 2 |
| 700 | 1 | _ | |a Hyogo, Hideyuki |b 3 |
| 700 | 1 | _ | |a Tjønneland, Anne |b 4 |
| 700 | 1 | _ | |a Eriksen, Anne Kirstine |b 5 |
| 700 | 1 | _ | |a Severi, Gianluca |0 0000-0001-7157-419X |b 6 |
| 700 | 1 | _ | |a Rothwell, Joseph |b 7 |
| 700 | 1 | _ | |a Laouali, Nasser |b 8 |
| 700 | 1 | _ | |a Katzke, Verena |0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4 |b 9 |u dkfz |
| 700 | 1 | _ | |a Kaaks, Rudolf |0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |b 10 |u dkfz |
| 700 | 1 | _ | |a Schulze, Matthias B |b 11 |
| 700 | 1 | _ | |a Palli, Domenico |0 0000-0002-5558-2437 |b 12 |
| 700 | 1 | _ | |a Sieri, Sabina |0 0000-0001-5201-172X |b 13 |
| 700 | 1 | _ | |a de Magistris, Maria Santucci |b 14 |
| 700 | 1 | _ | |a Tumino, Rosario |b 15 |
| 700 | 1 | _ | |a Sacerdote, Carlotta |0 0000-0002-8008-5096 |b 16 |
| 700 | 1 | _ | |a Derksen, Jeroen W G |b 17 |
| 700 | 1 | _ | |a Gram, Inger T |0 0000-0002-0031-4152 |b 18 |
| 700 | 1 | _ | |a Skeie, Guri |b 19 |
| 700 | 1 | _ | |a Sandanger, Torkjel M |b 20 |
| 700 | 1 | _ | |a Quirós, Jose Ramón |b 21 |
| 700 | 1 | _ | |a Crous-Bou, Marta |b 22 |
| 700 | 1 | _ | |a Sánchez, Maria-Jose |b 23 |
| 700 | 1 | _ | |a Amiano, Pilar |b 24 |
| 700 | 1 | _ | |a Colorado-Yohar, Sandra M |b 25 |
| 700 | 1 | _ | |a Guevara, Marcela |b 26 |
| 700 | 1 | _ | |a Harlid, Sophia |0 0000-0001-8540-6891 |b 27 |
| 700 | 1 | _ | |a Johansson, Ingegerd |b 28 |
| 700 | 1 | _ | |a Perez-Cornago, Aurora |b 29 |
| 700 | 1 | _ | |a Freisling, Heinz |0 0000-0001-8648-4998 |b 30 |
| 700 | 1 | _ | |a Gunter, Marc |b 31 |
| 700 | 1 | _ | |a Weiderpass, Elisabete |b 32 |
| 700 | 1 | _ | |a Heath, Alicia K |0 0000-0001-6517-1300 |b 33 |
| 700 | 1 | _ | |a Aglago, Elom |0 0000-0002-0442-3284 |b 34 |
| 700 | 1 | _ | |a Jenab, Mazda |0 0000-0002-0573-1852 |b 35 |
| 700 | 1 | _ | |a Fedirko, Veronika |0 0000-0002-7805-9913 |b 36 |
| 773 | _ | _ | |a 10.1002/ijc.34449 |g p. ijc.34449 |0 PERI:(DE-600)1474822-8 |n 11 |p 2257-2268 |t International journal of cancer |v 152 |y 2023 |x 0020-7136 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:212552 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2022-11-25 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2022-11-25 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-25 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b INT J CANCER : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b INT J CANCER : 2022 |d 2023-10-21 |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|